Sinclair Pharma Text-only version

Jump to navigation | Skip to content

Return to graphical version

Consolidated Income Statement
for the year eneded 30 June 2008

 
2008
  
2007
 
Pre-
Exceptional
 
Pre-
Exceptional
 
exceptional
items
 
exceptional
items
 
items
(note 4)
Total
  
items
(note 4 )
Total
 
Note
£'000
£'000
£'000
  
£'000
£'000
£'000
Revenue
30,278
—
30,278
  
23,178
—
23,178
Cost of Sales  
(10,380)
—
(10,830)
  
(8,087)
—
(8,087)
Gross profit
19,448
—
19,448
  
15,091
—
15,091
Selling, marketing and distribution costs
(8,444)
—
(8,444)
  
(7,195)
—
(7,195)
Administrative expenses  
(11,803)
2,997
(8,806)
  
(10,375)
(1,467)
(11,842)
Operating profit/(loss)
(799)
2,997
2,198
  
(2,479)
(1,467)
(3,946)
Finance income
67
380
447
  
95
—
95
Finance costs
(741)
(330)
(1,071)
  
(129)
—
(129)
(Loss)/profit before taxation
(1,473)
3,047
1,574
  
(2,513)
(1,467)
(3,980)
Taxation
410
1,354
1,764
  
(226)
—
(226)
(Loss)/profit for the year  
(1,063)
4,401
3,338
  
(2,739)
(1,467)
(4,206)
Attributable to:
 
Minority interest
1
—
1
  
2
—
2
Equity holders of the Company  
(1,064)
4,401
3,337
  
(2,741)
(1,467)
(4,208)
   
(1,063)
4,401
3,338
  
(2,739)
(1,467)
(4,206)
 
 
(Loss)/earnings per share (basic)
(1.2)p
5.0p
3.8p
  
(3.2)p
(1.6)p
(4.8)p
(Loss)/earnings per share (diluted)
(1.2)p
4.8p
3.6p
  
(3.2)p
(1.6)p
(4.8)p

The notes on pages 40 to 64 are an integral part of these consolidated financial statements.